MedinCell enters into a technology agreement for long-acting injectable products. February 4, 2016 – CORPORATE, PRESS RELEASE MedinCell and Sandoz will develop and commercialize long-acting injectable products based on BEPO™ technology with a primary focus on oncology. The alliance is part of MedinCell’s network strategy to significantly improve current standard of care, reduce total costs […]
Post-operative pain management with BEPO™ November 4, 2015 First results of our scientific collaboration with Lapeyronie University Hospital, Dept of Anaesthesiology & Intensive Care and Montpellier University (INSERM U1046) about post-operative pain management based on bupivacaine BEPO™ formulation were presented last week at Anesthesiology 2015 in San Diego. Here is the poster.
Corbion and MedinCell form joint venture to supply resorb-able polymers for controlled drug release. August 10, 2015 Corbion and MedinCell are establishing a 50/50 joint venture for the supply of PEG (polyethylene glycol) and PLA (polylactic acid) based co-polymers in the field of controlled release drug delivery. The joint venture, CM Biomaterials, will sell the […]
Meet us @ BIO International Convention 2015 May 11, 2015 MedinCell is participating at the BIO International Convention in Philadelphia, USA – June 15-18, 2015, as a part of the French Pavilion – booth 2507 (map of the show). Don’t hesitate to come to meet us there or please contact Sebastien Enault if you wish to […]